Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study [Seeking Alpha]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Seeking Alpha
byakkayaAgios PharmaceuticalsNASDAQ:AGIOthe underlying causes of complex genetic disorders. With a strong commitment to patient-centered innovation, the company works on the forefront of medical science to create transformative therapies. Agios' commitment to exploring uncharted territories in the field of medicine potentially positions them well in an ever-competitive market. However, it is essential to evaluate the company's financials, products, and broader industry landscape to form a nuanced understanding of its future prospects.Financialssecond quarter of 2023PYRUKYNDcompared to $3.1 million in the same period last year, showcasing the market's response to the recently FDA-approved product.The cost of sales standing at $1.1 million suggests a healthy gross profit, and the R&D expenses decrease from $74.5 million to $68.9 million highlights a strategic realignment. This decrease in R&D, primarily from reduced headcount, might reflect a focus on specific research paths or an effor
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals price target raised to $34 from $32 at BofA [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners.MarketBeat
- Agios (AGIO) Gets 18.6% Boost from Aqvesme OK [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript [Seeking Alpha]Seeking Alpha
AGIO
Earnings
- 10/30/25 - Beat
AGIO
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 4
- AGIO's page on the SEC website